Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
| Autor: | Johanna J. Zirpel, Christin Gerhardt, Justus G. Garweg, Isabel B. Pfister |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Consecutive case series Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Macular Edema Cellular and Molecular Neuroscience Ophthalmology Ranibizumab Long term outcomes Diabetes Mellitus Medicine Humans Aflibercept Retrospective Studies Diabetic Retinopathy business.industry Long-term treatment Anti-VEGF Retrospective cohort study Diabetic retinopathy medicine.disease Sensory Systems eye diseases Bevacizumab Receptors Vascular Endothelial Growth Factor Diabetic macular oedema Diabetic macular oedema (DME) Intravitreal Injections Retinal Disorders medicine.symptom business Real-world studies Switzerland medicine.drug |
| Zdroj: | Graefe's Archive for Clinical and Experimental Ophthalmology |
| ISSN: | 1435-702X 0721-832X |
| Popis: | Objective To assess the long-term visual outcomes in eyes with symptomatic diabetic macular oedema (DME) under intravitreal treatment (IVT) in a clinical routine setting. Methods Patients with newly diagnosed DME were included in this retrospective study if they had received at least three IVTs and a follow-up period ≥ 2 years. Due to altered treatment patterns since the approval of ranibizumab for DME in 2012, patients were subdivided according to their first IVT before 2013 (group 1) or thereafter (group 2). The primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time. Results Of 217 eyes (191 patients) with DME, 151 eyes (117 patients) fulfilled the inclusion criteria (63 eyes in the first period, 88 in the second period). Mean follow-up time was 7.9 ± 3.1 (group 1) and 4.1 ± 1.4 years (group 2; p p = 0.44), but not thereafter (after 2 years in group 1: + 4.4 ± 15.0, group 2: + 8.3 ± 13.0 ETDRS letters; p = 0.038). During the first year, group 1 patients received less clinical examinations (group 1: 6.6 ± 3.3, group 2: 7.5 ± 2.1; p = 0.007) and less injections (group 1: 3.6 ± 2.7, group 2: 6.1 ± 2.7; p Conclusion A greater visual gain, in response to more intensive treatment during the first year, was maintained for at least 5 years in group 2 subjects. Our data confirm that in a real-world setting, early intensive treatment results in satisfying long-term visual outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink